Biomea Fusion, Inc. (BMEA)
- Previous Close
10.13 - Open
9.99 - Bid 10.06 x 200
- Ask 10.11 x 600
- Day's Range
9.91 - 10.34 - 52 Week Range
3.61 - 22.74 - Volume
428,170 - Avg. Volume
771,751 - Market Cap (intraday)
365.361M - Beta (5Y Monthly) -0.45
- PE Ratio (TTM)
-- - EPS (TTM)
-3.90 - Earnings Date Jul 31, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
32.63
Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.
biomeafusion.comRecent News: BMEA
View MorePerformance Overview: BMEA
Trailing total returns as of 10/3/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BMEA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BMEA
View MoreValuation Measures
Market Cap
365.00M
Enterprise Value
258.77M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
3.51
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-48.20%
Return on Equity (ttm)
-85.09%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-139.65M
Diluted EPS (ttm)
-3.90
Balance Sheet and Cash Flow
Total Cash (mrq)
113.29M
Total Debt/Equity (mrq)
9.95%
Levered Free Cash Flow (ttm)
-63.63M